Network views for personalized medicine

Proteomics - Clinical Applications

Volumn 7, Issue 5-6, 2013, Pages 384-387

  Vlahou, Antonia ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Biomarkers; Bladder cancer; Network; Validation

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; DISEASE MARKER; EARLY DIAGNOSIS; GOOD CLINICAL PRACTICE; HUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEOMICS;

HUMANS; INDIVIDUALIZED MEDICINE; PROTEIN INTERACTION MAPS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84879440425     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200121     Document Type: Article

References (15)

1. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
2. Mischak, H., Allmaier, G., Apweiler, R., Attwood, T. et al., Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2010, 2, 46ps42.
3. Borrebaeck, C. A. K., Viewpoints in clinical proteomics: when will proteomics deliver clinically useful information? Proteomics Clin. Appl. 2012, 6, 343-345.
4. Remily-Wood, E. R., Liu, R. Z., Xiang, Y., Chen, Y. et al., A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin. Appl. 2011, 5, 383-396.
5. Hood, B. L., Stewart, N. A., Conrads, T. P., Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation. Clin. Lab. Med. 2009, 29, 115-138.
6. Knepper, M. A., Common sense approaches to urinary biomarker study design. J. Am. Soc. Nephrol. 2009, 20, 1175-1178.
7. Mischak, H., Ioannidis, J. P. A., Argiles, A., Attwood, T. K. et al., Implementation of proteomic biomarkers: making it work. Eur. J. Clin. Invest. 2012, 42, 1027-1036
8. Lotan, Y., Shariat, S. F., Schmitz-Drager, B. J. et al., Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol. Oncol. 2010, 28, 441-448.
9. Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E. et al., ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 2013, 63, 4-15.
10. Frantzi, M., Makridakis, M., Vlahou, A., Biomarkers for bladder cancer aggressiveness. Curr. Opin. Urol. 2012, 22, 390-396.
11. Ru, Y., Dancik, G. M., Theodorescu, D., Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr. Opin. Urol. 2011, 21, 420-427.
12. Van Tilborg, A. A., Bangma, C. H., Zwarthoff, E. C., Bladder cancer biomarkers and their role in surveillance and screening. Int. J. Urol. 2009, 16, 23-30.
13. Dyla{ogonek}g, T., Jehenson, P., van de Loo, J. W., Sanne, J. L., Basic and clinical proteomics from the EU health research perspective Proteomics Clin. Appl. 2010, 4, 888-891.
14. Vlahou, A., Back to the future in bladder cancer research. Expert Rev. Proteomics 2011, 8, 295-297.
15. Grossman, H. B., Dinney, C. P., Schmitz-Dräger, B. J., Goebell, P. J., The international bladder cancer network. Urol. Oncol. 2010, 28, 375-376.